Hansa Biopharma 2Q net loss SEK178.9M, est. loss SEK125.3M

Hansa Biopharma 2Q net loss SEK178.9M, est. loss SEK125.3M

Hansa Biopharma AB (STO:HNSA) has released its interim financial report for the period January-June 2025. The company reported a net loss of SEK178.9 million for the second quarter (Q2) 2025, compared to a net loss of SEK207.9 million for the same period last year. The estimated loss for the full year 2025 is SEK125.3 million [1].

Key Financial Highlights:

- Revenue: Hansa Biopharma's revenue for Q2 2025 was SEK49.1 million, a 38% increase compared to Q2 2024's SEK34.3 million. For the first half of 2025, revenue was SEK115.5 million, a 52% increase over the same period in 2024 [1].
- Product Sales: IDEFIRIX product revenues increased by 76% in Q2 2025 compared to the same period last year. IDEFIRIX sales for Q2 2025 totaled SEK47.8 million, up from SEK27.2 million in Q2 2024. For the first half of 2025, IDEFIRIX sales amounted to SEK113.5 million, representing approximately 80% of full year 2024 sales [1].
- Operating Expenses: SG&A expenses for Q2 2025 were SEK90.5 million, up from SEK88.2 million in Q2 2024. R&D expenses were SEK95.8 million for Q2 2025, compared to SEK91.7 million in Q2 2024 [1].
- Cash Position: Hansa Biopharma's cash and short-term investments stood at SEK354.4 million at the end of Q2 2025, compared to SEK705.0 million at the end of Q2 2024 [1].

Pipeline Progress and Financing:

Hansa Biopharma successfully secured additional financing and restructured its debt agreement with NovaQuest. The company raised approximately SEK232 million (US $24.3 million) through a directed cash share issue, which was used to offset US $14.9 million of outstanding debt. The remaining debt will be paid in fixed cash payments in June 2027, June 2028, and June 2029. A true-up payment of approximately US $14.9 million is due on January 31, 2026, which may be settled in cash or equity at the company's discretion [1].

The company remains on track to report data from the 20-HMedIdeS-17 study (ConfIdeS) and expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2025, following data readout. Enrollment is ongoing in the GNT-018-IDES trial, a Phase 2 study in Crigler Najjar, and the Phase 1b trial SRP-9001-104 with Sarepta remains on track for an initial data readout later this year [1].

Conclusion:

Hansa Biopharma's Q2 2025 financial results reflect a significant increase in IDEFIRIX product sales and a successful capital raise to support ongoing clinical trials. The company's cash runway has been extended into Q2 2026, providing time to focus on near-term catalysts and strategic pipeline decisions. The company's financial performance and pipeline progress position it well for continued growth and commercialization in the biopharmaceutical sector.

References:

[1] https://agenparl.eu/2025/07/17/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results/